Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock par value $0.012 per share
-
Shares outstanding
-
41M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
1.46M
-
Shares change
-
-539K
-
Total reported value, excl. options
-
$6.17M
-
Value change
-
-$1.61M
-
Put/Call ratio
-
0.21
-
Number of buys
-
15
-
Number of sells
-
-16
-
Price
-
$4.24
Significant Holders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) as of Q4 2020
47 filings reported holding ORMP - ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share as of Q4 2020.
ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.46M shares
of 41M outstanding shares and own 3.55% of the company stock.
Largest 10 shareholders include MORGAN JESS S & CO INC (577K shares), RENAISSANCE TECHNOLOGIES LLC (372K shares), Frontier Wealth Management LLC (71.9K shares), BlackRock Inc. (68.7K shares), Qube Research & Technologies Ltd (54.3K shares), MARSHALL WACE, LLP (36.6K shares), Squarepoint Ops LLC (30.4K shares), MILLENNIUM MANAGEMENT LLC (23.5K shares), LMR Partners LLP (23.1K shares), and PNC Financial Services Group, Inc. (21.2K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.